CRISPR Therapeutics (CRSP) recently outlined a packed 2026 roadmap, highlighting global CASGEVY commercialization, fresh regulatory submissions, and multiple readouts and trial starts across its in vivo and CAR T gene editing programs.

The recent roadmap update and upcoming J.P. Morgan Healthcare Conference appearance come after a mixed year for the stock. The 1-year total shareholder return of 46.45% contrasts with a 21.78% decline in the 3 month share price return and a 71.67% total shareholder return decline over five years. This suggests momentum has cooled in the short term even as long term holders have seen substantial swings in value.

If CRISPR Therapeutics has you looking more broadly at gene editing and drug development, it could be a good moment to scan other healthcare stocks that might fit your watchlist.

With CRISPR Therapeutics trading at $56.18 and sitting at a reported 72% intrinsic discount and 49% below the average analyst target, the key question is whether this signals genuine undervaluation or whether the market already reflects future growth.

Price to Book of 2.8x: Is it justified?

At a last close of US$56.18, CRISPR Therapeutics is trading on a P/B of 2.8x, which is flagged as good value versus peers but slightly expensive versus the broader US biotech group.

P/B compares the company’s market value to its net assets on the balance sheet, which matters a lot for a loss making biotech where earnings do not yet offer much guidance. For CRISPR Therapeutics, this 2.8x figure is described as good value against a peer average P/B of 22x, suggesting investors are paying far less for each dollar of book value than for many directly comparable names.

The same 2.8x P/B is described as expensive versus the wider US biotech industry average of 2.6x, so the stock sits just above that broader benchmark. Put together, the picture is of a company priced low against its closer peer set, but carrying a slight premium to the wider industry.

Result: Price-to-book of 2.8x (ABOUT RIGHT)

However, you also need to weigh risks such as ongoing net losses of US$488.297m and the execution hurdles that come with multiple complex clinical programs.

Another View: What Our DCF Model Suggests

The SWS DCF model presents a very different picture, with CRISPR Therapeutics at US$56.18 compared with an estimated fair value of US$202.79. That gap suggests the market price is well below this model’s view of worth. This raises the question of whether the cash flow assumptions are too generous or the market is too cautious.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 884 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own CRISPR Therapeutics Narrative

If you are not fully on board with this view or prefer to lean on your own work, you can build a fresh thesis in just a few minutes. To begin, use Do it your way.

A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Hunting For Your Next Investment Idea?

If CRISPR Therapeutics is on your radar, do not stop there. Broaden your opportunity set while the market is still throwing up very different types of ideas.

• Scan for value focused ideas by checking out these 884 undervalued stocks based on cash flows that might offer discounted cash flow potential compared to their current prices.
• Target growth themes by reviewing these 25 AI penny stocks that tie into artificial intelligence trends across different parts of the market.
• Collect potential income ideas by assessing these 13 dividend stocks with yields > 3% that could complement higher risk growth names in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.